Salvage brachytherapy for localized prostate cancer after radiotherapy failure

Urology

Volumn 53, Issue 1, 1999, Pages 2-10

  Grado, Gordon L ^a   Collins, Joseph M ^a   Kriegshauser, J Scott ^a   Balch, Carrie S ^a   Grado, Mary M ^a   Swanson, Gregory P ^b   Larson, Thayne R ^a   Wilkes, Mahlon M ^c   Navickis, Roberta J ^c  

^a MAYO CLINIC   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c Hygeia Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; PALLADIUM; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DYSURIA; FOLLOW UP; HEMATURIA; HUMAN; MALE; MALE GENITAL TRACT CANCER; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM HEMORRHAGE; RECTUM ULCER; URINE INCONTINENCE;

ACTUARIAL ANALYSIS; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT FAILURE;

EID: 0032905040     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00492-0     Document Type: Article

References (52)

1. Kaplan I.D., Cox R.S., Bagshaw M.A. Prostate specific antigen after external beam radiotherapy for prostatic cancer followup . J Urol. 149:1993;519-522.
2. Stamey T.A., Kabalin J.N., Ferrari M. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J Urol. 141:1989;1084-1087.
3. Lee W.R., Hanlon A.L., Hanks G.E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer. The relationship between nadir level and disease-free survival. J Urol. 156:1996;450-453.
4. Hanks G.E., Martz K.L., Krall J.M., et al. Analysis of independent variables affecting survival after recurrence of prostate cancer. Int J Radiat Oncol Biol Phys. 16:1989;1431-1435.
5. Lai P.P., Perez C.A., Lockett M.A. Prognostic significance of pelvic recurrence and distant metastasis in prostate carcinoma following definitive radiotherapy. Int J Radiat Oncol Biol Phys. 24:1992;423-430.
6. Holzman M., Carlton C., Scardino P.T. The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer. J Urol. 146:1991;1578-1582.
7. Zietman A.L., Shipley W.U., Willett C.G. Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. Cancer. 71:1993;959-969.
8. Zincke H. Radical prostatectomy and exenterative procedures for local failure after radiotherapy with curative intent comparison of outcomes . J Urol. 147:1992;894-899.
9. Rainwater L.M., Zincke H. Radical prostatectomy after radiation therapy for cancer of the prostate feasibility and prognosis . J Urol. 140:1988;1455-1459.
10. Thompson I.M., Rounder J.B., Spence C.R., et al. Salvage radical prostatectomy for adenocarcinoma of the prostate. Cancer. 61:1988;1464-1466.
11. Neerhut G.J., Wheeler T., Cantini M., et al. Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol. 140:1988;544-549.
12. Moul J.W., Paulson D.F. The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer. 68:1991;1265-1271.
13. Link P., Freiha F.S. Radical prostatectomy after definitive radiation therapy for prostate cancer. Urology. 37:1991;189-192.
14. Ahlering T.E., Lieskovsky G., Skinner D.G. Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. J Urol. 147:1992;900-902.
15. Stein A., Smith R.B., deKernion J.B. Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate. Urology. 40:1992;197-200.
16. Pontes J.E., Montie J., Klein E., et al. Salvage surgery for radiation failure in prostate cancer. Cancer. 71:1993;976-980.
17. Rogers E., Ohori M., Kassabian V.S., et al. Salvage radical prostatectomy outcome measured by serum prostate specific antigen levels . J Urol. 153:1995;104-110.
18. Catalona W.J. Management of cancer of the prostate. N Engl J Med. 331:1994;996-1004.
19. Cohen J.K., Miller R.J., Rooker G.M., et al. Cryosurgical ablation of the prostate two year prostate specific antigen and biopsy results . Urology. 47:1996;395-400.
20. Miller R.J. Jr, Cohen J.K., Shuman B., et al. Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma. Cancer. 77:1996;1510-1514.
21. Bales G.T., Williams M.J., Sinner M., et al. Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Urology. 46:1995;676-680.
22. Waxman S., Stevens A.K., Walsh R.A., et al. Management of asymptomatic rising PSA after prostatectomy or radiation therapy. Oncology (Huntingt). 11:1997;457-465.
23. Patel B.G., Parsons C.L., Bidair M., et al. Cryoablation for carcinoma of the prostate. J Surg Oncol. 63:1996;256-264.
24. Stokes S.H., Real J.D., Adams P.W., et al. Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 37:1997;337-341.
25. 125iodine prostate implants for recurrent carcinomas after external beam irradiation preliminary results . Cancer. 45:1980;2717-2724.
26. 125iodine implantation and pelvic lymphadenectomy for prostatic cancer with special references to patients who have failed external beam therapy as their initial mode of therapy. J Urol. 126:1981;620-622.
27. Butler E.B., Scardino P.T., Teh B.S., et al. The Baylor College of Medicine experience with gold seed implantation. Semin Surg Oncol. 13:1997;406-418.
28. Dattoli M., Cash J., Ross R., et al. Neoadjuvant hormone therapy and palladium-103 brachytherapy as salvage for locally recurrent prostate cancer. Proc Am Soc Clin Oncol. 16:1997;314a.
29. Grado G.L., Larson T.R., Balch C.S., et al. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys. 42:1998;289-298.
30. Utz D.C., Farrow G.M. Pathologic differentiation and prognosis of prostatic carcinoma. JAMA. 209:1969;1701-1703.
31. Gleason D.F. Histologic grading and clinical staging of prostatic carcinoma. Tannenbaum M. Urologic Pathology The Prostate . 1977;171-198 Lea & Febinger, Philadelphia.
32. 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol. 130:1983;283-286.
33. Nag S. Transperineal iodine-125 implantation of the prostate under transrectal ultrasound and fluoroscopic control. Endocurie/Hypertherm Oncol. 1:1985;207-211.
34. Ragde H., Blasko J.C., Schumacher D. Use of transrectal ultrasound in transperineal iodine-125 seeding for prostate cancer methodology . J Endourol. 3:1989;209-218.
35. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 . Med Phys. 22:1995;209-234.
36. 125I transperineal prostate seed implants on commercial treatment planning systems. Int J Radiat Oncol Biol Phys. 37:1997;737-741.
37. Wheeler J.A., Zagars G.K., Ayala A.G. Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression. Cancer. 71:1993;3783-3787.
38. Schellhammer P.F., el-Mahdi A.M., Wright G.L., et al. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology. 42:1993;13-20.
39. Critz F.A., Tarlton R.S., Holladay D.A. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation. Cancer. 75:1995;2383-2391.
40. Schellhammer P.F., Kuban D.A., el-Mahdi A.M. Local failure after definitive radiation or surgical therapy for carcinoma of the prostate and options for prevention and therapy. Urol Clin North Am. 18:1991;485-499.
41. Kuban D.A., el-Mahdi A.M., Schellhammer P.F. Prognosis in patients with local recurrence after definitive irradiation for prostatic carcinoma. Cancer. 63:1989;2421-2425.
42. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 35:1996;875-879.
43. D'Amico A.V., Coleman C.N. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer the jury is still out . J Clin Oncol. 14:1996;304-315.
44. 125I prostate implantation. Int J Radiat Oncol Biol Phys. 37:1997;559-563.
45. Blasko J.G., Grimm P.D., Padge H. External beam irradiation with palladium-103 implantation for prostate carcinoma. Int J Radiat Oncol Biol Phys. 30:(suppl 1):1994;219.
46. 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol. 154:1995;1096-1099.
47. 125iodine implantation for localized prostate cancer using percutaneous approach. J Urol. 153:1995;1020-1025.
48. Ragde H., Blasko J.C., Grimm P.D., et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 80:1997;442-453.
49. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
50. Arterbery V.E., Frazier A., Dalmia P., et al. Quality of life after permanent prostate implant. Semin Surg Oncol. 13:1997;461-464.
51. Cespedes R.D., Pisters L.L., von Eschenbach A.C., et al. Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate results in 143 patients . J Urol. 157:1997;237-240.
52. Lerner S.E., Blute M.L., Zincke H. Critical evaluation of salvage surgery for radiorecurrent/resistant prostate cancer. J Urol. 154:1995;1103-1109.